Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.56 |
| ▸ | GRM1 | Q13255 | 10/20 | 0.53 |
| ▸ | GRM5 | P41594 | 9/20 | 0.53 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.52 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.50 |
| ▸ | CDK7 | P50613 | 1/20 | 0.48 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.48 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.48 |
| ▸ | QDPR | P09417 | 2/20 | 0.47 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31174297 | 1.00 | NAMPT (0.56) | NAMPTGRM1GRM5PDK4TLR7 | |
| SCHEMBL24309445 | 0.91 | NAMPT (0.54) | NAMPTGRM1GRM5PDK4TLR7 | |
| SCHEMBL29566866 | 0.91 | NAMPT (0.54) | NAMPTGRM1GRM5PDK4TLR7 | |
| SCHEMBL24309522 | 0.91 | NAMPT (0.54) | NAMPTGRM1GRM5PDK4TLR7 | |
| SCHEMBL29566392 | 0.91 | NAMPT (0.54) | NAMPTGRM1GRM5PDK4TLR7 | |
| SCHEMBL15178435 | 0.91 | NAMPT (0.54) | NAMPTGRM1GRM5PDK4TLR7 | |
| SCHEMBL15184378 | 0.90 | NAMPT (0.53) | NAMPTGRM1GRM5PDK4TLR7 | |
| SCHEMBL19703157 | 0.90 | NAMPT (0.53) | NAMPTGRM1GRM5PDK4TLR7 | |
| SCHEMBL30722230 | 0.90 | NAMPT (0.53) | NAMPTGRM1GRM5PDK4TLR7 | |
| SCHEMBL1198658 | 0.90 | NAMPT (0.53) | NAMPTGRM1GRM5PDK4TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118515604-A | Preparation method of Akt inhibitor intermediate | 上海陶术生物科技有限公司 | 2024-08-20 | — | — | CN | claimed |
| CN-118515604-A | Preparation method of Akt inhibitor intermediate | 上海陶术生物科技有限公司 | 2024-08-20 | — | — | CN | disclosed |
| EP-3468961-B1 | 5-[3-[PIPERIDIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2020-06-10 | — | — | EP | disclosed |
| US-10550100-B2 | 5-[3-[piperzin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating E.G. osteoarthritis | GALAPAGOS NV (BE) | 2020-02-04 | — | — | US | disclosed |
| US-10550100-B2 | 5-[3-[piperzin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating E.G. osteoarthritis | GALAPAGOS NV (BE) | 2020-02-04 | — | — | US | disclosed |
| US-20190300503-A1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2019-10-03 | — | — | US | disclosed |
| US-20190300503-A1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2019-10-03 | — | — | US | disclosed |
| WO-2017211667-A1 | 5-[3-[PIPERIDIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2017-12-14 | — | — | WO | disclosed |
| US-20050080096-A1 | Condensed heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080096-A1 | Condensed heterocyclic compounds | PARP1, PARP2, PARP3 | NAMPT 908/4885GRM1 4138/4885GRM5 4743/4885 |
| US-20190300503-A1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | ADAMTS5, ADAMTS4, ADAMTS1 | NAMPT 1820/4885GRM1 4600/4885GRM5 2955/4885 |
| US-10550100-B2 | 5-[3-[piperzin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating E.G. osteoarthritis | ADAMTS5, ADAMTS4, ADAMTS1 | NAMPT 1895/4885GRM1 4411/4885GRM5 2997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.